Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Èíôåêöèîííûå áîëåçíè > Ôîðóì äëÿ îáùåíèÿ âðà÷åé-èíôåêöèîíèñòîâ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 26.05.2011, 16:44
Àâàòàð äëÿ easl
easl easl âíå ôîðóìà
Âðà÷-èíôåêöèîíèñò
      
 
Ðåãèñòðàöèÿ: 05.02.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 18,445
Ïîáëàãîäàðèëè 5,215 ðàç(à) çà 4,965 ñîîáùåíèé
easl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Èíòåðåñíûå êëèíè÷åñêèå ñëó÷àè è ìåäèöèíñêèå ññûëêè

Kiss of Death
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
In the Commentary (page 2567), the parenthetical in the final sentence of the third paragraph, “(e.g., intravenous immune globulin for hepatitis A infection),” should be deleted, so that the sentence reads, “The treatment of other viral infections is generally not initiated until a specific diagnosis has been made.” The article is correct at NEJM.org.
.
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 04.08.2011, 11:46
Àâàòàð äëÿ easl
easl easl âíå ôîðóìà
Âðà÷-èíôåêöèîíèñò
      
 
Ðåãèñòðàöèÿ: 05.02.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 18,445
Ïîáëàãîäàðèëè 5,215 ðàç(à) çà 4,965 ñîîáùåíèé
easl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
TB Rapid Test Performs Well in Children
Overall, the Xpert MTB/RIF assay demonstrated high sensitivity and specificity; in smear-negative cases, a second induced specimen increased sensitivity from 33% to 61%.

The Xpert MTB/RIF, a new molecular test to identify Mycobacterium tuberculosis and rifampin resistance, performs with high sensitivity and specificity in adult populations (JW Infect Dis Apr 27 2011). Might it also work well for children, in whom diagnosis is complicated by low numbers of mycobacteria and difficulty in obtaining good specimens?

To find out, researchers conducted a prospective study involving children aged 15 years who were hospitalized in South Africa with suspected pulmonary tuberculosis (TB; N=452; 24% with HIV infection). After a 2- to 3-hour fast, sputum induction was done by a trained research nurse. Whenever possible, a second induced specimen was obtained later the same day or the following day. All specimens were cultured and also tested with the Xpert MTB/RIF assay.

Six percent of the children had a TB-positive smear, 16% had a positive culture result (defined as definite TB), and 13% had a positive MTB/RIF result. The initial MTB/RIF test detected all definite cases that were smear positive but only 33% of those that were smear negative; a second test (performed in 385 children) improved the detection of smear-negative cases to 61%. Overall, the sensitivity and specificity were 59% and 99%, respectively, for one MTB/RIF test, and 76% and 99% for two. MTB/RIF results were available within a median of 1 day (vs. 12 days for culture).

Comment: For detecting TB in children, the MTB/RIF test is substantially better than smear microscopy, especially when two induced specimens are examined. Although the WHO has recommended using a single MTB/RIF test in adults with suspected TB, the authors and an editorialist note the benefit (and the extra cost) of performing a second one in children whose first specimen tests negative. The authors point out the need for increased capacity for sputum induction in children — and the continued need for better methods to diagnose childhood TB.

— Mary E. Wilson, MD

Published in Journal Watch Infectious Diseases August 3, 2011
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 19.08.2011, 15:55
Àâàòàð äëÿ easl
easl easl âíå ôîðóìà
Âðà÷-èíôåêöèîíèñò
      
 
Ðåãèñòðàöèÿ: 05.02.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 18,445
Ïîáëàãîäàðèëè 5,215 ðàç(à) çà 4,965 ñîîáùåíèé
easl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
CCO HIV inPractice™:
A free point-of-care textbook and database resource from the leader in HIV medical education.
CCO HIV inPractice™ is a unique Web site designed to provide easy access to accurate, clinically relevant information to improve care for HIV-infected patients. The program was launched in 2009 and the contents are reviewed and updated on an ongoing basis.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
DmitryTro îäîáðèë(à): ...íå òîëüêî ÂÈ×, åùå è ãåïàòèò, è îíêîëîãèÿ http://www.clinicaloptions.com/ - âåñüìà ñâåæî è èíòåðåñíî
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 22.08.2011, 17:24
Àâàòàð äëÿ easl
easl easl âíå ôîðóìà
Âðà÷-èíôåêöèîíèñò
      
 
Ðåãèñòðàöèÿ: 05.02.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 18,445
Ïîáëàãîäàðèëè 5,215 ðàç(à) çà 4,965 ñîîáùåíèé
easl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Targeted Testing for Latent TB
Use of a simple four-variable risk-factor questionnaire could have reduced testing by 91%.


In the U.S., testing for latent tuberculosis infection (LTBI) is currently recommended only for individuals who are at high risk for infection, based on clinical factors. Such targeting greatly reduces the number of people tested and does not negatively affect disease control efforts. The U.S. military is still testing all recruits, even though the case rate of TB is far lower in recruits than that in the general U.S. population.

In a recent study involving Army recruits at Fort Jackson, South Carolina, researchers evaluated the accuracy of a risk-factor questionnaire (RFQ) in predicting a positive result on three currently available screening tests (the tuberculin skin test [TST] and 2 interferon- release assays: the QuantiFERON-TB Gold In-Tube [QFT-GIT] test and the T-SPOT.TB [T-Spot] test).

A total of 1783 recruits completed the study and had valid results (either positive or negative) on all three tests. Of these, 105 (5.9%) had a positive TST. A four-variable RFQ model, with a sensitivity of 79% and a specificity of 92% for predicting TST positivity, showed the best bias-variance trade-off. The variables included in this model were (1) close contact with a person who had active TB, (2) birth in a country with TB prevalence 20 per 100,000, (3) residence with a parent who was born outside the U.S., and (4) prior positive TST results. Only 166 participants (9%) were positive for any of the four variables; targeted testing of just those recruits would have reduced TB testing by 91%. The four-variable RFQ had a sensitivity of 41% and a specificity of 91% in predicting positive results on either the QFT-GIT or the T-Spot.

Impact of targeted testing for latent tuberculosis infection using commercially available diagnostics.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 25.08.2011, 14:11
Àâàòàð äëÿ cactus1972
cactus1972 cactus1972 âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 14.01.2010
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,200
Ñêàçàë(à) ñïàñèáî: 54
Ïîáëàãîäàðèëè 355 ðàç(à) çà 331 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 9
cactus1972 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcactus1972 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcactus1972 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcactus1972 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcactus1972 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcactus1972 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcactus1972 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcactus1972 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcactus1972 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcactus1972 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåcactus1972 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ìíå ïîêàçàëàñü èíòåðåñíîé ýòà èíôîðìàöèÿ. Õîòÿ, îíà, íàâåðíî, áîëåå äëÿ ïàðàçèòîëîãîâ, íåæåëè äëÿ èíôåêöèîíèñòîâ.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Öèòàòà:
Objective: The purpose of this study was to determine whether mothers infected with T. gondii have an elevated risk of schizophrenia or related disorders and whether the risk depends on IgG antibody level.

Method: In a register-based prospective cohort study of 45,609 women born in Denmark, the level of T. gondii-specific IgG antibodies was measured in connection with childbirth between 1992 and 1995. Women were followed up from the date of delivery until 2008.

Results: A significant positive association between T. gondii IgG antibody level and schizophrenia spectrum disorders was found. Mothers with the highest IgG level had a relative risk of 1.73 (95% confidence interval [CI]=1.12–2.62) compared with mothers with the lowest IgG level. For schizophrenia, the relative risk was 1.68 (95% CI=0.77–3.46). When the mothers were classified according to IgG level, only those with the highest IgG levels had a significantly higher risk of schizophrenia spectrum disorders.

Conclusions: Women with high levels of T. gondii-specific IgG antibodies have a significantly elevated risk of developing schizophrenia spectrum disorders.
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 04.08.2012, 17:46
Àâàòàð äëÿ genbytu
genbytu genbytu âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 29.04.2009
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 3,112
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 959 ðàç(à) çà 949 ñîîáùåíèé
genbytu ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìågenbytu ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìågenbytu ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìågenbytu ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìågenbytu ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìågenbytu ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìågenbytu ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìågenbytu ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìågenbytu ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìågenbytu ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìågenbytu ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Öèòàòà:
In May of 2010, two communities (Truenococha and Santa Marta) reported to be at risk of vampire bat depredation were surveyed in the Province Datem del Marañón in the Loreto Department of Perú. Risk factors for bat exposure included age less than or equal to 25 years and owning animals that had been bitten by bats. Rabies virus neutralizing antibodies (rVNAs) were detected in 11% (7 of 63) of human sera tested. Rabies virus ribonucleoprotein (RNP) immunoglobulin G (IgG) antibodies were detected in the sera of three individuals, two of whom were also seropositive for rVNA. Rabies virus RNP IgM antibodies were detected in one respondent with no evidence of rVNA or RNP IgG antibodies. Because one respondent with positive rVNA results reported prior vaccination and 86% (six of seven) of rVNA-positive respondents reported being bitten by bats, these data suggest nonfatal exposure of persons to rabies virus, which is likely associated with vampire bat depredation.

Êîììåíòàðèè ê ñîîáùåíèþ:
Kuleshov îäîáðèë(à): Ñïàñèáî. Óäèâëþ ñâîèõ èíôåêöèîíèñòîâ. À òî äëÿ íèõ è ïðîòîêîë Ìèëóîêè áûë êóëüòóðíûì øîêîì.
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 02.10.2015, 17:20
Àâàòàð äëÿ easl
easl easl âíå ôîðóìà
Âðà÷-èíôåêöèîíèñò
      
 
Ðåãèñòðàöèÿ: 05.02.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 18,445
Ïîáëàãîäàðèëè 5,215 ðàç(à) çà 4,965 ñîîáùåíèé
easl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Effectiveness of Sofosbuvir-based Regimens in Genotype 1 and 2 Hepatitis C Virus Infection in 4026 U.S. Veterans [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 08.02.2016, 19:06
Àâàòàð äëÿ easl
easl easl âíå ôîðóìà
Âðà÷-èíôåêöèîíèñò
      
 
Ðåãèñòðàöèÿ: 05.02.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 18,445
Ïîáëàãîäàðèëè 5,215 ðàç(à) çà 4,965 ñîîáùåíèé
easl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Managing HBV in pregnancy. Prevention, Prophylaxis, Treatment and Follow-up
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 06.06.2017, 19:30
Àâàòàð äëÿ easl
easl easl âíå ôîðóìà
Âðà÷-èíôåêöèîíèñò
      
 
Ðåãèñòðàöèÿ: 05.02.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 18,445
Ïîáëàãîäàðèëè 5,215 ðàç(à) çà 4,965 ñîîáùåíèé
easl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êðàòêî î âèðóñíûõ ãåïàòèòàõ A, B, C, D, E ñ EASL-2017
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #10  
Ñòàðûé 21.12.2018, 15:04
Àâàòàð äëÿ easl
easl easl âíå ôîðóìà
Âðà÷-èíôåêöèîíèñò
      
 
Ðåãèñòðàöèÿ: 05.02.2008
Ãîðîä: Áàêó
Ñîîáùåíèé: 18,445
Ïîáëàãîäàðèëè 5,215 ðàç(à) çà 4,965 ñîîáùåíèé
easl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeasl ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Recurrent Optic Neuritis as the Only Manifestation of Chronic Hepatitis B Virus Flare
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #11  
Ñòàðûé 04.02.2020, 16:55
Àâàòàð äëÿ Igoryaka
Igoryaka Igoryaka âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 29.07.2018
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 4,111
Ñêàçàë(à) ñïàñèáî: 109
Ïîáëàãîäàðèëè 2,593 ðàç(à) çà 2,500 ñîîáùåíèé
Igoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgoryaka ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïîäðîáíîå îïèñàíèå îäíîãî èç ïåðâûõ çàêîí÷åííûõ ñëó÷àåâ êîðîíàâèðóñíîé èíôåêöèè (nCov-2019) â ÑØÀ.
Àâòîð ïåðåâîäà êàðäèîëîã Áðîäñêèé Ì. Ñ. (ïîðòàë doctornarabote.ru):

"Ïîäðîáíî îïèñàíà äèíàìèêà ñèìïòîìîâ, ëàáîðàòîðíûõ äàííûõ è ðåíòãåíîëîãè÷åñêîé êàðòèíû (î÷åíü íàãëÿäíûå èëëþñòðàöèè).

Ñàìà ñòàòüÿ çäåñü - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Ñëó÷àé, î êîòîðîì èäåò ðå÷ü, çàôèêñèðîâàí ó 35-ëåòíåãî ìóæ÷èíû, êîòîðûé îáðàòèëñÿ â îòäåëåíèå íåîòëîæíîé ïîìîùè íà 4-é äåíü çàáîëåâàíèÿ ñ æàëîáàìè íà êàøåëü è ñóáúåêòèâíî îùóùàåìóþ ëèõîðàäêó (ÿ òàê ïîíèìàþ, èçìåðåíèå òåìïåðàòóðû â äîìàøíèõ óñëîâèÿõ ó íèõ íå òàê ïîïóëÿðíî, êàê ó íàñ, âåçäå âñòðå÷àåòñÿ ôðàçà «ñóáúåêòèâíî îùóùàåìàÿ ëèõîðàäêà»), êîòîðûé ñîîáùèë, ÷òî âåðíóëñÿ 15 ÿíâàðÿ ïîñëå ïîåçäêè ê ñâîåé ñåìüå â Êèòàé (Óõàíü). Îí ñîîáùèë, ÷òî îí íå áûë íà ðûíêå ìîðåïðîäóêòîâ â Óõàíå, íå êîíòàêòèðîâàë ñ áîëüíûìè ÎÐÇ âî âðåìÿ ïîåçäêè â Êèòàé. Íî ñëûøàë èíôîðìàöèþ CDC îá óãðîçå ýïèäåìèè è ïîýòîìó îáðàòèëñÿ ê ìåäèêàì ïðè ïåðâûõ ñèìïòîìàõ.  àíàìíåçå ïàöèåíòà ãèïåðòðèãëèöåðèäåìèÿ, â îñòàëüíîì – «ïðàêòè÷åñêè çäîðîâ», íå êóðèò. Ïðè îñìîòðå òåìïåðàòóðà 37.2°C, ÀÄ 134/87 mm Hg, ×ÑÑ = 110/ìèí., ×ÄÄ = 16/ìèí., ñàòóðàöèÿ – 96% ïðè äûõàíèè îêðóæàþùèì âîçäóõîì. Ïðè àóñêóëüòàöèè ë¸ãêèõ âûÿâëåíû õðèïû, ñòàðòîâàÿ ðåíòãåíîãðàììà ïàòîëîãèè íå âûÿâèëà (ðèñ.1). Ñêðèíèíã-òåñò íà ãðèïï À è B – îòðèöàòåëüíû. Òåñò (NAAT) ìàçêà èç çåâà è íîñà íà âèðóñû ÎÐÇ (áûëè ãîòîâû óæå ÷åðåç 48 ÷àñîâ), - ãðèïï À è B, ïàðàãðèïï, ðåñïèðàòîðíî-ñèíöèòèàëüíûé âèðóñ, ðèíîâèðóñ, àäåíîâèðóñ è ÷åòûðå èçâåñòíûõ øòàììà êîðîíàâèðóñà, âûçûâàþùèå çàáîëåâàíèÿ ó ÷åëîâåêà ((HKU1, NL63, 229E, and OC43), - òàêæå äàëè îòðèöàòåëüíûé ðåçóëüòàò.

20 ÿíâàðÿ CDC (Öåíòð ïî êîíòðîëþ è ïðîôèëàêòèêå çàáîëåâàíèé ÑØÀ) ñîîáùèë, ÷òî â ìàçêàõ èç çåâà è íîñà áîëüíîãî îáíàðóæåí 2019-nCoV.

Ïðè ïîñòóïëåíèè â ñòàöèîíàð áîëüíîé æàëîâàëñÿ íà óïîðíûé ñóõîé êàøåëü, â òå÷åíèå ïîñëåäóþùèõ 2-õ äíåé – íà òîøíîòó è ðâîòó. Áîëè â ãðóäíîé êëåòêå èëè îäûøêè íå áûëî. Âèòàëüíûå ïîêàçàòåëè îñòàâàëèñü â ïðåäåëàõ íîðìàëüíûõ çíà÷åíèé. Ïðè îñìîòðå âûÿâëåíà ñóõîñòü ñëèçèñòûõ îáîëî÷åê, â îñòàëüíîì – áåç îñîáåííîñòåé.

Áîëüíîé ïîëó÷àë ïîääåðæèâàþùóþ òåðàïèþ, 2 ëèòðà ôèçðàñòâîðà è îíäàíñåòðîí äëÿ îáëåã÷åíèÿ ðâîòû.

Ñî 2-ãî ïî 5-é äåíü ãîñïèòàëèçàöèè (ñ 6-ãî ïî 9-é äåíü çàáîëåâàíèÿ (äàëåå - ÄÁ)) æèçíåííûå ïîêàçàòåëè îñòàâàëèñü â öåëîì ñòàáèëüíûìè, çà èñêëþ÷åíèåì ýïèçîäîâ ëèõîðàäêè è òàõèêàðäèè (ðèñ.2). Ñîõðàíÿëèñü æàëîáû íà íåïðîäóêòèâíûé êàøåëü, ïîÿâèâøóþñÿ ñëàáîñòü. Óòðîì 2-ãî äíÿ ãîñïèòàëèçàöèè ó áîëüíîãî áûë ÷àñòûé æèäêèé ñòóë è äèñêîìôîðò â æèâîòå. Âòîðîé ïîäîáíûé ýïèçîä íàáëþäàëñÿ íî÷üþ òîãî æå äíÿ. Îáðàçöû ïëàçìû êðîâè, ôåêàëèé, è ïîâòîðíî – èç çåâà è íîñà îòïðàâëåíû â ëàáîðàòîðèþ. Âñå êðîìå îáðàçöîâ êðîâè îêàçàëèñü ïîëîæèòåëüíû íà íàëè÷èå 2019-nCoV.
Ëå÷åíèå â ýòîò ïåðèîä îñòàâàëîñü ïîääåðæèâàþùèì. Òàê, ïî íåîáõîäèìîñòè áîëüíîé ïîëó÷àë àöåòàìèíîôåí (ïàðàöåòàìîë) 650 mg êàæäûå 4 ÷àñà è 600 mg èáóïðîôåíà êàæäûå 6 ÷àñîâ. Îí òàêæå ïîëó÷àë 600 mg ãâàéôåíåçèíà äëÿ îáëåã÷åíèÿ êàøëÿ è ïðèìåðíî 6 ëèòðîâ ôèçðàñòâîðà çà ïåðâûå 6 äíåé ãîñïèòàëèçàöèè.

 ëàáîðàòîðíûõ ïîêàçàòåëÿõ íà 3-é è 5-é äåíü ãîñïèòàëèçàöèè (ñ 7-ãî ïî 9-é ÄÁ) íàáëþäàëàñü ëåéêîïåíèÿ è óìåðåííàÿ òðîìáîöèòîïåíèÿ, ïîâûøåíèå ÊÔÊ. Êðîìå òîãî, íàáëþäàëèñü îòêëîíåíèÿ â ïå÷åíî÷íûõ ïðîáàõ - ÙÔ, ÀëÀò, ÀñÀÒ, ËÄà (öèôðû â ñòàòüå), êîòîðûå îêàçàëèñü ïîâûøåíû íà 5-é äåíü ãîñïèòàëèçàöèè.

Ó÷èòûâàÿ ïåðåìåæàþùóþñÿ ëèõîðàäêó, áûëè âçÿòû ïðîáû êðîâè íà ñòåðèëüíîñòü, íà 4-é äåíü ðîñòà êóëüòóðû íå ïîëó÷åíî.

Ðåíòãåíîãðàììà ÎÃÊ íà 3-é äåíü ãîñïèòàëèçàöèè (7-é ÄÁ) îñòàâàëàñü íîðìàëüíîé, îäíàêî ïîâòîðíàÿ ðåíòãåíîãðàììà, âûïîëíåííàÿ íî÷üþ íà 5-é ÄÃ, âûÿâèëà ïðèçíàêè ïíåâìîíèè â íèæíåé äîëè ëåâîãî ëåãêîãî (ðèñ. 4). Ýòà íàõîäêà ñîâïàëà ïî âðåìåíè ñ ïàäåíèåì ñàòóðàöèè ïî äàííûì ïóëüñîêñèìåòðèè äî 90% ïðè äûõàíèè îêðóæàþùèì âîçäóõîì. Ñ 6-ãî äíÿ íà÷àòà ðåñïèðàòîðíàÿ ïîääåðæêà èíãàëÿöèåé êèñëîðîäà ÷åðåç íîñîâóþ êàíþëþ ñî ñêîðîñòüþ 2ë/ìèí. Ó÷èòûâàÿ èçìåíåíèÿ â êëèíè÷åñêîé êàðòèíå è âåðîÿòíîñòü ãîñïèòàëüíîé ïíåâìîíèè, íà÷àòà àíòèáàêòåðèàëüíàÿ òåðàïèÿ - âàíêîìèöèí (1750ìã íàãðóçî÷íîé äîçû ïëþñ 1,0 êàæäûå 8 ÷àñîâ âíóòðèâåííî) + öåôåïèì (êàæäûå 8 ÷àñîâ âíóòðèâåííî).

Íà 6-é äåíü ãîñïèòàëèçàöèè (10-é ÄÁ), ÷åòâåðòàÿ ðåíòãåíîãðàììà âûÿâèëà ëèíåéíûå òåíè â íèæíèõ îòäåëàõ îáîèõ ë¸ãêèõ, óêàçûâàþùèå íà ðàçâèòèå àòèïè÷íîé ïíåâìîíèè (ðèñ. 5), ïðè àóñêóëüòàöèè âûñëóøèâàëèñü õðèïû ñ îáåèõ ñòîðîí.

Ó÷èòûâàÿ ðåíòãåíîëîãè÷åñêóþ êàðòèíó, íåîáõîäèìîñòü ðåñïèðàòîðíîé ïîääåðæêè, ñîõðàíÿþùóþñÿ ôåáðèëüíóþ ëèõîðàäêó, ïîçèòèâíûå ðåçóëüòàòû òåñòîâ íà 019-nCoV RNA â ìíîãî÷èñëåííûõ ïðîáàõ è îïóáëèêîâàííûå îò÷åòû î ðàçâèòèè (ïðè äàííîé èíôåêöèè) òÿæåëîé ïíåâìîíèè è ïîÿâëåíèè ïðèçíàêîâ ïîäîáíîé ïíåâìîíèè ó äàííîãî áîëüíîãî, ïðèíÿòî ðåøåíèå îá ýêñïåðèìåíòàëüíîé ïðîòèâîâèðóñíîé òåðàïèè.

Ëå÷åíèå ðåìäåçèâèðîì âíóòðèâåííî (ýêñïåðèìåíòàëüíîå ïðåäëåêàðñòâî-àíàëîã íóêëåîòèäà) íà÷àòî âå÷åðîì 7-ãî äíÿ ãîñïèòàëèçàöèè, ïðîõîäèëî áåç ïîáî÷íûõ ýôåêòîâ. Òîãäà æå îòìåíåí âàíêîìèöèí, íà ñëåäóþùèé äåíü – öåôèïèì, ïîñëå íåîäíîêðàòíûõ îòðèöàòåëüíûõ òåñòîâ íà ïðîêàëüöèòîíèí è ÏÖÐ íàçàëüíûõ ïðîá íà ìåòèöèëëèí-óñòîé÷èâûé Staphylococcus aureus.

Íà 8-é äåíü ãîñïèòàëèçàöèè (12 ÄÁ), ñîñòîÿíèå áîëüíîãî óëó÷øèëîñü. Ðåñïèðàòîðíàÿ ïîääåðæêà áûëà îòìåíåíà, ñàòóðàöèÿ ïîâûñèëàñü äî 94-96% ïðè äûõàíèè îêðóæàþùèì âîçäóõîì. Äâóñòîðîííèå õðèïû èñ÷åçëè. Àïïåòèò ïàöèåíòà óëó÷øèëñÿ, äðóãèõ ñèìïòîìîâ, êðîìå ïåðèîäè÷åñêè âîçíèêàþùåãî ñóõîãî êàøëÿ è ðèíîðåè, íå íàáëþäàëîñü.

Íà 30 ÿíâàðÿ 2020ã áîëüíîé îñòàåòñÿ â áîëüíèöå. Ëèõîðàäêè íåò, êàê è îñòàëüíûõ ñèìïòîìîâ, çà èñêëþ÷åíèåì ñóõîãî êàøëÿ, èíòåíñèâíîñòü êîòîðîãî ñíèæàåòñÿ.

Îïóáëèêîâàí îò÷åò î ïåðâîì çàêîí÷åííîì ñëó÷àå íîâîé êîðîíàðîâèðóñíîé èíôåêöèè â ÑØÀ –
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Ïîëîæèòåëüíàÿ äèíàìèêà äîñòèãíóòà íà ôîíå ïðèìåíåíèÿ ðåìäåçèâèðà, ýêñïåðèìåíòàëüíîãî ïðåäëåêàðñòâà - àíàëîãà íóêëåîòèäà, îáíàäåæèâàþùèå íàáëþäåíèÿ î ïðèìåíåíèè êîòîðîãî âî âðåìÿ ýïèäåìèè ëèõîðàäêè Ýáîëà â Çàïàäíîé Àôðèêå â 2013-2016ãã áûëè îïóáëèêîâàíû ðàíåå.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Íà ìîìåíò ïóáëèêàöèè ïàöèåíò åù¸ â ñòàöèîíàðå, íî òåìïåðàòóðà òåëà íîðìàëèçîâàëàñü, õîòÿ ñîõðàíÿåòñÿ êàøåëü.

Ïîäòâåðäèëèñü ïðåäïîëîæåíèÿ î ïåðåäà÷å âèðóñà îò èíôèöèðîâàííîãî ñóáúåêòà óæå â èíêóáàöèîííîì ïåðèîäå – [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Öåíòð ïî êîíòðîëþ è ïðîôèëàêòèêå çàáîëåâàíèé ÑØÀ (the Centers for Disease Control and Prevention (CDC)) ðåêîìåíäóåò êðîìå ñòàíäàðòíîé çàùèòû îò âîçäóøíî-êàïåëüíîé è êîíòàêòíîé ïåðåäà÷è - çàùèòó ãëàç. Îáñóæäàåòñÿ ïåðåäà÷à âèðóñà ÷åðåç êîíúþíêòèâó(!)"
__________________
__________________
Ñ óâàæåíèåì, Èãîðü Àëåêñàíäðîâè÷
Îòâåòèòü ñ öèòèðîâàíèåì
  #12  
Ñòàðûé 05.02.2020, 10:27
Àâàòàð äëÿ Tihoma
Tihoma Tihoma âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 11.08.2009
Ãîðîä: Ñ-Ïåòåðáóðã
Ñîîáùåíèé: 2,188
Ñêàçàë(à) ñïàñèáî: 13
Ïîáëàãîäàðèëè 630 ðàç(à) çà 588 ñîîáùåíèé
Tihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Èíòåðåñíî, à åñòü âûçäîðîâåâøèå ÁÅÇ ïðîòèâîâèðóñíîé òåðàïèè?
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 13:52.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.